ReviewCancers2026
The Role of Cytology, Histology and Molecular Pathology in the Diagnostic Process of Thyroid Nodules.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, thyroid nodule diagnosis and classification have been updated by two major developments: the fifth edition of the World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors classification 2022), which includes thyroid neoplasms, and the third edition of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) (2023). Importantly, these classification systems converge in terminology, improving clinicopathologic correlation between fine-needle aspiration cytology (FNAC) and surgical pathology and supporting more consistent risk-based management. In parallel, molecular testing has assumed a growing role, particularly for indeterminate FNA categories, as reflected in contemporary practice recommendations. Moreover, the 2025 American Thyroid Association guidelines recalibrate postoperative risk stratification in differentiated thyroid cancer by reasserting histopathology as the cornerstone of clinical decision-making. In this review, we summarize key updates in thyroid FNAC reporting, histopathologic classification, and the practical application of molecular pathology for the evaluation and management of thyroid nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.